Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R)

Huntington Beach, California and Amsterdam (ots/PRNewswire)
-- Agendia, a world leader in molecular cancer diagnostics,
announced today that Palmetto GBA, California's Part B Medicare
administrator, has established coding guidelines for the company's
MammaPrint test. MammaPrint is Agendia's FDA-cleared breast cancer
recurrence test, which has been reimbursed by payors since 2008.

Patients across the United States can now submit claims for the
MammaPrint test directly to Palmetto GBA in California where the test
results are analyzed. The coding guidelines for healthcare providers
are available at the Centers for Medicare and Medicaid Services (CMS)
website at http://www.cms.hhs.gov/mcd/viewlcd.asp?lcd_id=30376&lcd_ve
rsion=5&show=all.

"Palmetto's decision to include MammaPrint in their reimbursement
guidelines will provide greater access to this test for more women
and their doctors when faced with difficult treatment decisions
around breast cancer," said Dr. Richard Bender, Chief Medical Officer
of Agendia.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test
cleared by the U.S. Food and Drug Administration (FDA). FDA clearance
under the in vitro diagnostic multivariate index assay (IVDMIA)
guidelines requires clinical and analytical validation and reporting
systems to ensure that patient safety and efficacy are addressed.
Highly accurate, MammaPrint identifies patients with early
metastasis-patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown
that chemotherapy particularly reduces early metastasis risk. In
planning treatment, the MammaPrint test results, in addition to other
clinical information and pathology tests, provide doctors with a
clear rationale to evaluate the benefits of chemotherapy

All MammaPrint tests are conducted in Agendia's CLIA-accredited
service laboratory. Breast cancer recurrence assays currently
marketed by other manufacturers have not been subject to the rigorous
FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting-edge
genomics platform for tumor gene expression profiling, the company's
tests help physicians more accurately tailor cancer treatments.
Agendia markets four products, with several new genomic tests under
development. In addition, Agendia collaborates with pharmaceutical
companies to develop highly effective personalized drugs in the area
of oncology. The Company was awarded the 2008 North American Oncology
Clinical Diagnostics Healthcare Innovation Award by Frost &
Sullivan. Agendia is based in Huntington Beach, California, and in
Amsterdam, The Netherlands.

MEDIA CONTACTS:
Hans Herklots Valerie Delva
Head of Corporate Communications Account Executive
Agendia Ricochet Public Relations
+31-20-462-1557 Office +1-212-679-3300 x131 Office
+31-620-083-509 Mobile vdelva@ricochetpr.com
hans.herklots@agendia.com

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
MEDIA CONTACTS: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
hans.herklots@agendia.com; Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, vdelva@ricochetpr.com